Company
Every investor coverage indicates participated in a round Genentech raised.
Companies Genentech acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Genentech. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Starpharma grew annual revenue on a Genentech licence payment, cut its loss, and completed a $30 million entitlement offer, giving it cash into 2028 to advance its cancer pipeline.
Kazia Therapeutics reviews its 2019 clinical trial data read-outs at its AGM and recalls a share placement that strengthened its balance sheet and brought new institutional investors onto its register.
Cancer drug developer Kazia pitched to AusBiotech Invest, highlighting its Genentech-designed brain cancer candidate GDC-0084, ongoing trials, and solid finances after a recent institutional placement.
ChemGenex Pharmaceuticals has hired oncology drug developer Dr Adam Craig as its chief medical officer, its third senior clinical appointment lately, as it prepares its cancer drug omacetaxine for a regulatory filing.
Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.